Charmacy Pharmaceutical Co., Ltd.
HKEX:2289.HK
9.3 (HKD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 4,403.633 | 4,175.279 | 3,793.618 | 3,991.711 | 3,492.783 | 3,935.246 | 4,095.835 | 3,669.781 | 3,397.133 | 3,014.059 | 2,401.231 |
Cost of Revenue
| 4,110.89 | 3,906.67 | 3,559.501 | 3,754.308 | 3,272.135 | 3,700.124 | 3,888.416 | 3,489.935 | 3,232.431 | 2,877.618 | 2,297.253 |
Gross Profit
| 292.744 | 268.61 | 234.117 | 237.403 | 220.648 | 235.122 | 207.419 | 179.847 | 164.702 | 136.441 | 103.978 |
Gross Profit Ratio
| 0.066 | 0.064 | 0.062 | 0.059 | 0.063 | 0.06 | 0.051 | 0.049 | 0.048 | 0.045 | 0.043 |
Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 133.244 | 49.647 | 48.402 | 45.7 | 46.504 | 54.159 | 49.503 | 38.755 | 40.38 | 37.162 | 33.972 |
Selling & Marketing Expenses
| 37.56 | 112.92 | 103.449 | 85.975 | 77.4 | 73.983 | 68.078 | 51.778 | 40.296 | 35.757 | 25.137 |
SG&A
| 170.804 | 165.049 | 151.559 | 143.043 | 128.15 | 130.186 | 119.556 | 92.648 | 80.676 | 72.919 | 59.109 |
Other Expenses
| 51.384 | -0.372 | -0.128 | -0.037 | 0.066 | 0.219 | 0.239 | 0 | 0 | 0 | 0 |
Operating Expenses
| 222.188 | 116.084 | 163.418 | 154.943 | 138.803 | 143.552 | 125.554 | 90.237 | 103.678 | 72.407 | 58.102 |
Operating Income
| 66.195 | 93.487 | 74.424 | 88.076 | 85.197 | 99.081 | 83.718 | 83.459 | 84.026 | 63.522 | 44.869 |
Operating Income Ratio
| 0.015 | 0.022 | 0.02 | 0.022 | 0.024 | 0.025 | 0.02 | 0.023 | 0.025 | 0.021 | 0.019 |
Total Other Income Expenses Net
| 1.225 | 28.567 | 0.593 | -33.334 | 0.639 | -35.425 | 3.932 | 2.917 | -42.451 | -17.587 | -15.555 |
Income Before Tax
| 67.42 | 122.054 | 32.981 | 54.742 | 55.045 | 63.655 | 59.857 | 76.081 | 41.575 | 45.935 | 29.314 |
Income Before Tax Ratio
| 0.015 | 0.029 | 0.009 | 0.014 | 0.016 | 0.016 | 0.015 | 0.021 | 0.012 | 0.015 | 0.012 |
Income Tax Expense
| 16.075 | 31.673 | 9.828 | 14.186 | 14.891 | 18.893 | 15.562 | 19.623 | 15.216 | 9.49 | 7.095 |
Net Income
| 51.345 | 90.472 | 23.153 | 40.556 | 40.153 | 45.433 | 44.76 | 59.348 | 26.359 | 36.445 | 22.219 |
Net Income Ratio
| 0.012 | 0.022 | 0.006 | 0.01 | 0.011 | 0.012 | 0.011 | 0.016 | 0.008 | 0.012 | 0.009 |
EPS
| 0.48 | 0.84 | 0.21 | 0.38 | 0.37 | 0.42 | 0.41 | 0.52 | 0.32 | 0.46 | 0 |
EPS Diluted
| 0.48 | 0.84 | 0.21 | 0.38 | 0.37 | 0.42 | 0.41 | 0.52 | 0.32 | 0.46 | 0 |
EBITDA
| 136.923 | 119.188 | 107.553 | 111.034 | 110.15 | 113.81 | 99.391 | 94.937 | 93.008 | 73.247 | 54.836 |
EBITDA Ratio
| 0.031 | 0.029 | 0.027 | 0.028 | 0.03 | 0.03 | 0.024 | 0.026 | 0.027 | 0.024 | 0.023 |